Key Takeaways:
- Pfizer halts development of its weight management drug, boosting Viking Therapeutics stock.
- Viking Therapeutics emerges as a potential leader in the weight loss market.
- Analysts project significant upside potential for VKTX with an "Outperform" consensus rating.
Pfizer's (PFE) strategic decision to cease the development of its weight management drug, danuglipron, has catalyzed a notable surge in Viking Therapeutics (VKTX, Financial) shares. As a result, Viking's stock experienced a significant rise of approximately 10%, reaching $24.43. This strategic pivot by Pfizer potentially paves the way for Viking Therapeutics to strengthen its position as a prominent partnership contender in the competitive weight loss drug space.
Analyst Price Predictions
Examining the one-year price targets provided by 15 industry analysts, Viking Therapeutics Inc (VKTX, Financial) is projected to have an average target price of $97.40. Analysts offer a high estimate of $164.00 and a low estimate of $30.00, suggesting a potential upside of 312.71% from its current price of $23.60. For a deeper dive into these projections, investors can visit the detailed analysis on the Viking Therapeutics Inc (VKTX) Forecast page.
Brokerage Firm Recommendations
According to consensus data from 18 brokerage firms, Viking Therapeutics Inc (VKTX, Financial) garners an average brokerage recommendation of 1.7. This indicates an "Outperform" status on a recommendation scale where 1 corresponds to a Strong Buy and 5 signifies a Sell. This bullish outlook reflects the promising potential seen by analysts in Viking's strategic market positioning.
